<DOC>
	<DOCNO>NCT02876042</DOCNO>
	<brief_summary>The purpose registry evaluate effect BAROSTIM THERAPY BAROSTIM NEO system commercial setting subject recently implant CE-Marked indication resistant hypertension also evidence heart failure preserve ejection fraction ( HFpEF ) .</brief_summary>
	<brief_title>BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Sign Ethics Committee ( EC ) approve informed consent form registry . Implanted BAROSTIM NEO system accordance CEMark approve indication contraindication resistant hypertension within 30 day prior enrollment . BAROSTIM THERAPY yet chronically activate . Preimplant echocardiogram leave ventricular ejection fraction ≥ 50 % within 30 day prior implant . On stable , maximallytolerated , guidelinedirected cardiovascular medication least 30 day prior enrollment . Objective evidence heart failure accord follow criterion : Hospitalization heart failure within 12 month prior enrollment OR Echocardiographic evidence diastolic dysfunction ( LA Volume Index &gt; 34 ml/m2 OR E/e &gt; 13 ) within 30 day prior enrollment OR NTproBNP &gt; 220 pg/mL BNP &gt; 80 pg/mL ( atrial fibrillation , NTproBNP &gt; 600 Heart failure secondary reversible treatable condition , cardiac structural valvular disease , acute myocarditis pericardial constriction . Heart failure secondary right ventricular failure right ventricular myocardial infarction .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Preserved Ejection Fraction</keyword>
</DOC>